Internal Medicine, Gastroenterology · Erie, PA
NPI
1659302669
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
145 W 23rd St Ste 101
Erie, PA, 16502
Phone (814) 452-2767
Groups this clinician bills Medicare through
Medicare paid, 2024
$76K
666 services
Medicare patients, 2024
399
Average age 72
Drug cost, 2024
$1.1M
1,387 prescriptions
Company payments, 2025
$432
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Segun E Abogunde was code 99214 (office e&m - established), 96 times for 82 patients. In total Segun E Abogunde billed 666 services in 42 codes, and Medicare paid $76K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 96 | 82 | $87.05 | $8,357 |
| 99231 Hospital E&M - Subsequent | Facility | 61 | 41 | $38.73 | $2,362 |
| 45385 Colonoscopy - Lesion Removal | Office | 45 | 45 | $207.62 | $9,343 |
| 43239 Upper GI Endoscopy | Facility | 32 | 31 | $70.80 | $2,266 |
| 99213 Office E&M - Established | Office | 31 | 28 | $63.93 | $1,982 |
| 43235 Upper GI Endoscopy | Facility | 29 | 28 | $69.19 | $2,006 |
| 99222 Hospital E&M - Initial | Facility | 26 | 26 | $94.55 | $2,458 |
| 99221 Hospital E&M - Initial | Facility | 25 | 25 | $64.65 | $1,616 |
| 45385 Colonoscopy - Lesion Removal | Facility | 24 | 24 | $195.41 | $4,690 |
| 45380 Lower GI Endoscopy - Other | Office | 23 | 23 | $123.80 | $2,847 |
| 99232 Hospital E&M - Subsequent | Facility | 21 | 18 | $58.92 | $1,237 |
| 43239 Upper GI Endoscopy | Office | 18 | 18 | $78.94 | $1,421 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 17 | 17 | $169.41 | $2,880 |
| 99204 Office E&M - New | Office | 14 | 14 | $121.44 | $1,700 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Office | 13 | 13 | $178.33 | $2,318 |
By year: 2022 $74K for 784 services; 2023 $84K for 852 services; 2024 $76K for 666 services.
Medicare prescription drug claims, 2024
In 2024, the drug Segun E Abogunde prescribed most often to Medicare patients was Pantoprazole Sodium, with 224 prescriptions and refills. In total Segun E Abogunde wrote 1,387 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 224 | 418 | 57 | $1,971 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 122 | 122 | 118 | $8,498 |
| Famotidine Generic | 109 | 173 | 25 | $356 |
| Omeprazole Generic | 82 | 173 | 23 | $662 |
| Mesalamine Dr Mesalamine | 66 | 132 | 16 | $34K |
| Budesonide Ec Budesonide | 38 | 54 | 14 | $6,962 |
| Spironolactone Generic | 37 | 47 | Under 11 | $415 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 37 | 37 | 37 | $657 |
| Mesalamine Generic | 36 | 76 | Under 11 | $25K |
| Nortriptyline Hcl Generic | 33 | 57 | Under 11 | $359 |
| Budesonide Dr Budesonide | 33 | 49 | Under 11 | $3,750 |
| Mercaptopurine Generic | 33 | 77 | Under 11 | $4,210 |
| Furosemide Generic | 31 | 35 | Under 11 | $115 |
| Ursodiol Generic | 29 | 47 | Under 11 | $3,726 |
| Mesalamine Er Mesalamine | 28 | 36 | Under 11 | $5,594 |
Brand drugs: 248 claims; generic drugs: 1,139 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Segun E Abogunde $432 ($432 in general payments such as food, travel and fees) from 3 companies. The largest payer was Janssen Biotech, Inc. with $261.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.